Neurology and Therapy · Published 2026-06-09 · DOI 10.1007/s40120-026-00971-7
Piero Barbanti, Cinzia Aurilia, Massimo Filippi, Alberto Doretti, Florindo d’Onofrio, Paola Scatena, Rosario Vecchio, Roberta Messina, Luisa Vinciguerra, Angelo Ranieri, Francesco Baldisseri, Paola Torelli, Marco Russo, Carolina Cutrona, Giovanna Viticchi, Gabriella Egeo, Massimo Autunno, Francesca Pistoia, Cinzia Finocchi, Cecilia Camarda, Stefano Messina, Steno Rinalduzzi, Valeria Drago, Luigi Caputi, Monica Bandettini di Poggio, Simone Quintana, Antonio Salerno, Marco Bartolini, Giulia Fiorentini, Jesuely Spieckert de Souza, Fabrizio Di Stani, Stefano Bonassi, Annamaria Porreca, for the Italian Migraine Registry Study Group
PubPorta does not have an abstract for this article yet.
Read the article at the publisher →
Barbanti, P., Aurilia, C., Filippi, M., et al. (2026). Real-World Response and Super-Response to Eptinezumab over 48 Weeks in Migraine: The Prospective Multicenter EMBRACE III Study. Neurology and Therapy. https://doi.org/10.1007/s40120-026-00971-7